Meeting
2023 ASCO Genitourinary Cancers Symposium
Utilization of metastatic hormone sensitive prostate cancer (mHSPC) treatment in a community oncology practice setting.
Authors
Terri Conner
Vidence LLC, Boca Raton, FL
Terri Conner , Sreevalsa Appukkuttan , Sheldon Kong , Jay Jhaveri , Gilbert Ko , Bashir Kalayeh , LiHong He , Robert Sean Hauser , Arturo Loaiza-Bonilla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 86)
DOI
10.1200/JCO.2023.41.6_suppl.86
Abstract #
86
Poster Bd #
C13
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study.
First Author: Steven Yip
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical and patient factors associated with treatment intensification for metastatic castration-sensitive prostate cancer.
First Author: Sreevalsa Appukkuttan
Poster
2023 ASCO Annual Meeting
Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
First Author: Manish Kohli
Poster
2023 ASCO Genitourinary Cancers Symposium
Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.
First Author: Patrick Heckman